The Medical Advisor

Introduction Fenbendazole, a medication traditionally used as an anti-parasitic in veterinary medicine, is gaining unexpected attention for its potential benefits in treating chronic inflammatory and autoimmune conditions such as Multiple Sclerosis (MS), Rheumatoid Arthritis, and Osteoarthritis. While research on its use in humans remains limited and largely under the radar, emerging animal studies and personal testimonials suggest that fenbendazole and ivermectin—may offer significant relief for patients struggling with these debilitating diseases. This post explores the scientific background, shares compelling case reports, and highlights the growing interest in repurposing these medications for conditions far beyond their original scope. Fenbendazole for Multiple Sclerosis Is there any research on the utility of the anti-parasitic Fenbendazole in Multiple Sclerosis? Yes, but it's very well hidden, and you've likely never heard of it. I'll be honest, I hadn...

Cancer treatment has transformed dramatically over the past decade. From chemotherapy and radiation to targeted therapies, each advance has sought to tip the balance in favor of the patient. Now, cell-based immunotherapies — therapies that harness and engineer the body’s immune system to fight cancer — are taking center stage. Two of the most promising approaches are CAR-T and CAR-NK cell therapies. But what makes them different, and how are emerging innovations, including AI and NK cell expansion, shaping the future of immunotherapy? Understanding CAR-T Therapy CAR-T (Chimeric Antigen Receptor T-cell) therapy involves harvesting a patient’s T cells, genetically engineering them to recognize specific cancer antigens, and reinfusing them into the body. These modified T cells can detect and destroy cancer cells with remarkable precision. Strengths of CAR-T: High efficacy in blood cancers: Durable remissions have been reported in leukemia and lymphoma patients. Long-term immune memory: ...

Abstract The antiparasitic agents fenbendazole, mebendazole and ivermectin have recently emerged as promising candidates for adjunctive cancer therapy due to their multifaceted anticancer mechanisms and favorable safety profiles. Fenbendazole and mebendazole, benzimidazole derivatives, exert antitumor effects primarily through microtubule disruption and metabolic interference, inducing cell cycle arrest and apoptosis. Ivermectin, a macrocyclic lactone, complements these actions by inhibiting oncogenic signaling pathways such as STAT3, Wnt/β-catenin, and AKT/mTOR, while modulating immune responses.  Recently, ivermectin has been investigated not only in dual combinations with benzimidazoles but also as part of a triple‑agent strategy involving fenbendazole and mebendazole to potentially enhance anticancer effects. Systematic reviews of publicly reported case data suggest temporal associations between this triple combination and tumor regression across diverse malignancies, although...